Company news
Envveno Medical Corporation (NASDAQ:NVNO) news
Envveno Medical Corporation news releases on 6ix. Latest, Aug 2, 2024: EnVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate…
Press releases — page 2
EnVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 2, 2024
enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 31, 2024
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
June 20, 2024
EnVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9, 2024
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 7, 2024
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
April 8, 2024
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
February 28, 2024
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium
December 13, 2023
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
November 15, 2023
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update
October 25, 2023
enVVeno Medical Announces Private Placement of $28 Million
October 5, 2023
enVVeno Medical Announces New Expedited Development Plan for the enVVe(R) Transcatheter Based Replacement Venous Valve
October 5, 2023
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial
October 5, 2023
enVVeno Medical Reports Second Quarter 2023 Financial Results and Provides Corporate Update
July 30, 2023
enVVeno Medical to Host Virtual KOL Event on July 18, 2023
July 13, 2023
enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events
July 4, 2023
enVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate Update
April 30, 2023
enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
March 1, 2023
enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer
January 17, 2023
Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues
November 16, 2022
enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study
November 6, 2022
enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 26, 2022
enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous Valve for the Treatment of Chronic Venous Insufficiency
September 20, 2022
enVVeno Medical to Host Conference Call and Webcast on September 21, 2022
September 18, 2022
enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
August 15, 2022
enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 2, 2022
enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein
July 7, 2022
enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 1, 2022
enVVeno Medical Announces New U.S. VenoValve(R) Patent
April 10, 2022
enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
March 27, 2022
enVVeno Medical Announces ISO 13485 Certification
February 15, 2022
enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021
enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial
October 21, 2021
enVVeno Medical Corporation Successfully Completes Rebranding
September 30, 2021